Alzheimer’s Association International Conference 2021 (AAIC 2021)

Studies highlight potential link between COVID-19 and cognitive impairment

Roshini Claire Anthony, 20210827180001

Several studies presented at AAIC 2021 have suggested a possible link between COVID-19 and cognitive impairment.

High-dose aducanumab delays clinical decline across multiple domains in early AD

Elaine Soliven, 20210825000000

Treatment with high-dose aducanumab shows less clinical decline across individual items or domains of cognition, function, and behaviour compared with placebo in patients with early symptomatic Alzheimer’s disease (AD), according to the EMERGE* study presented at AAIC 2021.

Subjective cognitive decline risk may be higher in transgender vs cisgender adults

Roshini Claire Anthony, 20210823160001

Transgender adults had a higher likelihood of experiencing subjective cognitive decline (SCD) and SCD-related functional limitations compared with their cisgender counterparts, according to a study presented at AAIC 2021.

Short sleep duration in midlife may increase risk of dementia in later life

Elaine Soliven, 20210819000000

Midlife adults aged between 50 and 70 years who reported a short sleep duration of ≤6 hours/night had an increased risk of developing dementia later in life, according to a study presented at AAIC 2021.

Is keto neuroprotective in individuals with impaired cognition?

Audrey Abella, 20210818100000

Two studies presented at AAIC 2021 showed a potential neuroprotective effect of a ketogenic supplement or diet: In one study, consumption of a keto drink was associated with improvements in dorsal attention network (DAN) functional connectivity in mild cognitive impairment (MCI). Another study showed the keto diet’s potential to improve aberrant default mode network (DMN) connectivity patterns in adults at risk for Alzheimer’s disease (AD).

Better air quality tied to lower dementia risk

Pearl Toh, 20210814141000

Improved air quality was associated with a slower cognitive decline and a lower risk of developing dementia, according to studies presented at AAIC 2021.

New study highlights global prevalence of young-onset dementia

Roshini Claire Anthony, 20210813180001

A new systematic review and meta-analysis presented at AAIC 2021 has hinted at a high prevalence of young-onset dementia (YOD) worldwide.

Concomitant antidementia drug use does not affect pimavanserin safety, PK profile

Audrey Abella, 20210813100000

In patients with neurodegenerative and/or neurovascular disease (NDD) and dementia-related psychosis (DRP), concomitant antidementia medications (cADMs) used alongside the selective serotonin receptor modulating agent pimavanserin did not adversely impact its safety and pharmacokinetic (PK) profile, according to data presented at AAIC 2021.